{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:13:12Z","timestamp":1791666792287,"version":"4.3.4"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.autrev.2021.102927","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T11:34:24Z","timestamp":1630323264000},"page":"102927","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":164,"title":["Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis"],"prefix":"10.1016","volume":"21","author":[{"given":"Anuraag","family":"Jena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubhra","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parakkal","family":"Deepak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Kumar-M","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf I.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred H.J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"27","key":"10.1016\/j.autrev.2021.102927_bb0005","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.autrev.2021.102927_bb0010","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"10267","key":"10.1016\/j.autrev.2021.102927_bb0015","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.autrev.2021.102927_bb0020","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/2050640620972602","article-title":"Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: A systematic review and meta-analysis","volume":"9","author":"Singh","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.autrev.2021.102927_bb0025","doi-asserted-by":"crossref","first-page":"102613","DOI":"10.1016\/j.jaut.2021.102613","article-title":"Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies - A Danish population-based cohort study","volume":"118","author":"Attauabi","year":"2021","journal-title":"J Autoimmun"},{"issue":"4","key":"10.1016\/j.autrev.2021.102927_bb0030","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/gutjnl-2020-322539","article-title":"Effect of IBD medications on COVID-19 outcomes: results from an international registry","volume":"70","author":"Ungaro","year":"2021","journal-title":"Gut."},{"key":"10.1016\/j.autrev.2021.102927_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.dld.2021.05.015","article-title":"Vaccinations in patients with inflammatory bowel disease","author":"Macaluso","year":"2021","journal-title":"Dig Liver Dis"},{"issue":"10","key":"10.1016\/j.autrev.2021.102927_bb0040","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/rheumatology\/keq183","article-title":"Vaccinations in patients with immune-mediated inflammatory diseases","volume":"49","author":"Rahier","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"15","key":"10.1016\/j.autrev.2021.102927_bb0045","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA."},{"key":"10.1016\/j.autrev.2021.102927_bb0050","series-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2021"},{"issue":"4","key":"10.1016\/j.autrev.2021.102927_bb0055","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"issue":"10","key":"10.1016\/j.autrev.2021.102927_bb0060","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"key":"10.1016\/j.autrev.2021.102927_bb0065","series-title":"JBI Manual for Evidence Synthesis","article-title":"Chapter 7: Systematic reviews of etiology and risk","author":"Moola","year":"2020"},{"key":"10.1016\/j.autrev.2021.102927_bb0070","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.20479","article-title":"Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease","author":"Al-Janabi","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2021.102927_bb0075","article-title":"Vaccine in patients with systemic lupus Erythematosus and rheumatoid arthritis","author":"Ammitzb\u00f8ll","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.autrev.2021.102927_bb0080","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/annrheumdis-2021-220289","article-title":"Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases","volume":"80","author":"Boyarsky","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102927_bb0085","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220503","article-title":"Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2","author":"Braun-Moscovici","year":"2021","journal-title":"Annals of the Rheumatic Diseases Published Online First"},{"key":"10.1016\/j.autrev.2021.102927_bb0090","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220862","article-title":"Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis","author":"Bugatti","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102927_bb0095","article-title":"Antibody Responses to SARS-CoV-2 after Infection or Vaccination in Children and Young Adults with Inflammatory Bowel Disease","author":"Dailey","year":"2021","journal-title":"medRxiv [Preprint]"},{"key":"10.1016\/j.autrev.2021.102927_bb0100","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study","author":"Furer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102927_bb0105","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220272","article-title":"Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort","author":"Geisen","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102927_bb0110","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220597","article-title":"Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease","author":"Haberman","year":"2021","journal-title":"Annals of the Rheumatic Diseases Published Online First"},{"key":"10.1016\/j.autrev.2021.102927_bb0115","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2021.06.016","article-title":"Humoral Immune Response to mRNA COVID019 Vaccines among Patients with IBD","author":"Kappelman","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2021.102927_bb0120","article-title":"Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD [published online ahead of print, 2021 Apr 26]","author":"Kennedy","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2021.102927_bb0125","article-title":"The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study","volume":"8","author":"Mahil","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2021.102927_bb0130","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220781","article-title":"SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity","author":"Mrak","year":"2021","journal-title":"Annals Rheumat Dis Published Online First"},{"key":"10.1016\/j.autrev.2021.102927_bb0135","article-title":"Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2","author":"Deepak","year":"2021","journal-title":"medRxiv [Preprint]"},{"issue":"7","key":"10.1016\/j.autrev.2021.102927_bb0140","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/S2665-9913(21)00186-7","article-title":"Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis","volume":"3","author":"Rubbert-Roth","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2021.102927_bb0145","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220656","article-title":"High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases","author":"Ruddy","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2021.102927_bb0150","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00296-021-04910-7","article-title":"Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly","volume":"41","author":"Seyahi","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2021.102927_bb0155","article-title":"Immunogenicity of the ChAdOx1 nCoV-19 and the BBV152 vaccines in patients with autoimmune rheumatic diseases","author":"Shenoy","year":"2021","journal-title":"Medrxiv."},{"key":"10.1016\/j.autrev.2021.102927_bb0160","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220461","article-title":"SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases","author":"Simon","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102927_bb0165","article-title":"Brief report: Humoral and cellular immune responses to SARS-CoV-2 infection and vaccination in B cell depleted autoimmune patients","volume":"1","author":"Simon","year":"2021","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102927_bb0170","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220604","article-title":"Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases","author":"Spiera","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102927_bb0175","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220898","article-title":"Correspondence on \u2018Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort\u2019","author":"Valor-M\u00e9ndez","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102927_bb0180","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220736","article-title":"Correspondence on \u2018Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort\u2019","author":"Veenstra","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102927_bb0185","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220756","article-title":"Correspondence on \u2018SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response\u2019","author":"Westhoff","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2021.102927_bb0190","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2021.04.025","article-title":"Serologic response to messenger RNA coronavirus disease 2019 vaccines in inflammatory bowel disease patients receiving biologic therapies","volume":"161","author":"Wong","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2021.102927_bb0195","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220408","article-title":"Response to: \u2019Correspondence on \u2019SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response by Westhoff et al","author":"Bonelli","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102927_bb0200","first-page":"M21","article-title":"Absence of Humoral response after two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases: a case series","volume":"25","author":"Connolly","year":"2021","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.autrev.2021.102927_bb0205","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/ced.14631","article-title":"COVID-19 vaccination and patients with psoriasis under biologics: real-life evidence on safety and effectiveness from Italian vaccinated healthcare workers [published online ahead of print, 2021 Mar 5]","volume":"46","author":"Damiani","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.autrev.2021.102927_bb0210","article-title":"Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series","author":"Furer","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2021.102927_bb0215","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2021.05.044","article-title":"Effectiveness of SARS-CoV-2 vaccination in a veterans affairs cohort of patients with inflammatory bowel disease with diverse exposure to immunosuppressive medications","volume":"161","author":"Khan","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2021.102927_bb0220","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220539","article-title":"Correspondence on \u2018Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort\u2019","author":"Ramirez","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102927_bb0225","doi-asserted-by":"crossref","DOI":"10.1111\/ced.14723","article-title":"Young Dermatologists Italian Network, Damiani G. COVID-19 vaccines do not trigger psoriasis flares in patients with psoriasis treated with apremilast","author":"Pacifico","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.autrev.2021.102927_bb0230","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220677","article-title":"SARS-COV-2 vaccination after stem cell transplantation for scleroderma","author":"Rimar","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102927_bb0235","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220496","article-title":"Correspondence on \u2018Immunogenicity and safety of anti-SARS-Cov-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort\u2019","author":"Salviani","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2021.102927_bb0240","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/vaccines9050435","article-title":"Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA\/DNA SARS-CoV-2 vaccination","volume":"9","author":"Watad","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"10.1016\/j.autrev.2021.102927_bb0245","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/BOR.0000000000000776","article-title":"COVID-19 and autoimmune diseases","volume":"33","author":"Liu","year":"2021","journal-title":"Curr Opin Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2021.102927_bb0250","doi-asserted-by":"crossref","first-page":"102572","DOI":"10.1016\/j.autrev.2020.102572","article-title":"Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms","volume":"19","author":"Raucci","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.autrev.2021.102927_bb0255","doi-asserted-by":"crossref","first-page":"102597","DOI":"10.1016\/j.autrev.2020.102597","article-title":"Covid-19 and autoimmunity","volume":"19","author":"Ehrenfeld","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102927_bb0260","doi-asserted-by":"crossref","unstructured":"Simeng Lin, Nicholas A Kennedy, Aamir Saifuddin et al. Covid-19 vaccine-induced antibodies are attenuated and decay rapidly in infliximab treated patients, 30 July 2021, PREPRINT (Version 1) available at Research Square doi:10.21203\/rs.3.rs-755879\/v1.","DOI":"10.21203\/rs.3.rs-755879\/v1"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221002020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221002020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:24:58Z","timestamp":1761600298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997221002020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1568997221002020"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102927","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102927","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102927"}}